Literature DB >> 28736974

Topical sevoflurane for chronic venous ulcers infected by multi-drug-resistant organisms.

Adrián Imbernón-Moya1, Francisco Javier Ortiz-de Frutos2, Mónica Sanjuan-Alvarez3, Isabel Portero-Sanchez4, Raúl Merinero-Palomares5, Victoria Alcazar6.   

Abstract

Several anaesthetic drugs have demonstrated antibacterial properties in vitro. Anaesthetics can primarily affect the cell wall of both susceptible and multi-resistant bacteria. They may also have a synergistic effect with conventional antibiotics through an unknown mechanism. We present three cases of a chronic venous ulcer infected by multi-resistant bacteria refractory to conventional systemic antibiotics, including Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). Treatment with topical sevoflurane was performed for 1 month without systemic antibiotics. Patients with an MRSA infection showed progressive improvement with negative culture at the end of the treatment. Multi-drug-resistant P. aeruginosa infection persisted at the end of treatment with positive culture. The local adverse events were mild and transient, including heat, pruritus and erythema. Topical sevoflurane may have an antibacterial effect on sensitive and multi-resistant strains. It can allow more complete surgical cleaning, leaving a cleaner wound with less fibrin and necrotic tissue. This decreases the bacterial colonisation and therefore the infectious risk, the bad smell and the exudation. The simultaneous use of conventional antibiotics and topical sevoflurane can have a synergistic antimicrobial effect.
© 2017 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  Anaesthetic drugs; Antibiotics; Multi-resistant bacteria; Sevoflurane; Ulcers

Mesh:

Substances:

Year:  2017        PMID: 28736974      PMCID: PMC7950177          DOI: 10.1111/iwj.12794

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  5 in total

Review 1.  The impact of drugs used in anaesthesia on bacteria.

Authors:  I Bátai; M Kerényi; M Tekeres
Journal:  Eur J Anaesthesiol       Date:  1999-07       Impact factor: 4.330

2.  Antibacterial effect of sevoflurane and isoflurane.

Authors:  M Martínez-Serrano; M Gerónimo-Pardo; A Martínez-Monsalve; M D Crespo-Sánchez
Journal:  Rev Esp Quimioter       Date:  2017-02-15       Impact factor: 1.553

3.  Topical sevoflurane and healing of a post-operative surgical site superinfected by multi-drug-resistant Pseudomonas aeruginosa and susceptible Staphylococcus aureus in an immunocompromised patient.

Authors:  Juan Luis Rueda-Martínez; Manuel Gerónimo-Pardo; Angel Martínez-Monsalve; María Martínez-Serrano
Journal:  Surg Infect (Larchmt)       Date:  2014-12       Impact factor: 2.150

4.  Chronic venous ulcer treatment with topical sevoflurane.

Authors:  Adrián Imbernón; Cristina Blázquez; Ana Puebla; Micaela Churruca; Alejandro Lobato; Marcela Martínez; Antonio Aguilar; Miguel A Gallego
Journal:  Int Wound J       Date:  2015-07-21       Impact factor: 3.315

5.  Irrigation with Liquid Sevoflurane and Healing of a Postoperative, Recurrent Epidural Infection: A Potential Cost-Saving Alternative.

Authors:  Paula Ferrara; Esther Domingo-Chiva; Carmen Selva-Sevilla; Juan Campos-García; Manuel Gerónimo-Pardo
Journal:  World Neurosurg       Date:  2016-02-24       Impact factor: 2.104

  5 in total
  3 in total

1.  Pain reduction of topical sevoflurane vs intravenous opioids in pressure ulcers.

Authors:  F Dámaso Fernández-Ginés; Manuel Cortiñas-Sáenz; Desirée Agudo-Ponce; Ana Navajas-Gómez de Aranda; José A Morales-Molina; Carmen Fernández-Sánchez; Francisco Sierra-García; Héctor Mateo-Carrasco
Journal:  Int Wound J       Date:  2019-11-25       Impact factor: 3.315

Review 2.  The diagnosis of infection in chronic leg ulcers: A narrative review on clinical practice.

Authors:  Ut T Bui; Kathleen Finlayson; Helen Edwards
Journal:  Int Wound J       Date:  2019-01-29       Impact factor: 3.315

3.  Screening of antibacterial compounds with novel structure from the FDA approved drugs using machine learning methods.

Authors:  Wen-Xing Li; Xin Tong; Peng-Peng Yang; Yang Zheng; Ji-Hao Liang; Gong-Hua Li; Dahai Liu; Dao-Gang Guan; Shao-Xing Dai
Journal:  Aging (Albany NY)       Date:  2022-02-12       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.